References

Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries

2026 · External reference

Colorectal cancer

10.1016/s0140-6736(19)32319-0 · 2019 · External reference

Adjuvant therapy for stage II Colon cancer: ASCO guideline update

10.1200/jco.21.02538 · 2022 · External reference

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

10.1200/jco.2008.20.6771 · 2009 · External reference

Adjuvant chemotherapy for stage III Colon cancer

10.3390/cancers12092679 · 2020 · External reference

Metastatic colorectal cancer: ESMO Clinical practice guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2022.10.003 · 2023 · External reference

Resistance to targeted therapy in metastatic colorectal cancer: current status and new developments

10.3748/wjg.v29.i6.926 · 2023 · External reference

Blood CEA levels for detecting recurrent colorectal cancer

2015 · External reference

Significance of carcinoembryonic antigen detection in the early diagnosis of colorectal cancer: a systematic review and meta-analysis

10.4240/wjgs.v15.i12.2907 · 2023 · External reference

Limited detection of small (≤ 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection

10.1371/journal.pone.0189797 · 2017 · External reference

Imaging biomarkers for evaluating tumor response: RECIST and beyond

10.1186/s40364-021-00306-8 · 2021 · External reference

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells

2001 · External reference

Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples

2022 · External reference

Circulating mutant DNA to assess tumor dynamics

10.1038/nm.1789 · 2008 · External reference

Circulating Tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences

10.1158/1078-0432.ccr-21-2404 · 2022 · External reference

Circulating tumour DNA in predicting and monitoring survival of patients with locally advanced rectal cancer undergoing multimodal treatment: long-term results from a prospective multicenter study

10.1016/j.ebiom.2024.105548 · 2025 · External reference

Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon cancer

10.1056/nejmoa2200075 · 2022 · External reference

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial

10.1038/s41591-025-04030-w · 2025 · External reference

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

10.1038/s41591-024-03254-6 · 2024 · External reference

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

10.1186/s12885-020-07252-y · 2020 · External reference

From early detection to advanced therapies: how circulating tumor DNA is transforming the care of colorectal cancer

10.1007/s11912-025-01725-8 · 2025 · External reference

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis

10.1016/j.ctrv.2025.102999 · 2025 · External reference

Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis

2025 · External reference

International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors

10.1016/j.jlb.2025.100301 · 2025 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

2021 · External reference

Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the unicancer Prodige-14 trial

10.3390/cells8060516 · 2019 · External reference

Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases

10.1016/j.ebiom.2021.103498 · 2021 · External reference

Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer

10.1080/0284186x.2020.1806357 · 2020 · External reference

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer

10.1186/s13045-021-01089-z · 2021 · External reference

Preoperative liquid biopsy for optimal patient selection in metastatic colorectal cancer

10.1016/j.surg.2024.06.060 · 2025 · External reference

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer

10.1186/s12967-023-03884-3 · 2023 · External reference

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

10.3389/fonc.2022.973167 · 2022 · External reference

Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer

10.1002/ijc.33672 · 2021 · External reference

Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort

10.1016/j.annonc.2023.11.009 · 2024 · External reference

Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer

10.1016/j.ejso.2023.01.026 · 2023 · External reference

Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients

2023 · External reference

Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases

10.3389/fonc.2024.1418696 · 2024 · External reference

Impact of minimal residual disease on early recurrence of liver metastatic colorectal cancer

10.1111/cas.16442 · 2025 · External reference

MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer

10.1158/1078-0432.ccr-19-1996 · 2020 · External reference

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

10.1038/s41591-022-02115-4 · 2023 · External reference

Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: an exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection

10.3390/ijms231911529 · 2022 · External reference

Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases

2021 · External reference

Serial circulating tumor DNA mutational status in patients with KRAS-mutant metastatic colorectal cancer from the phase 3 AIO KRK0207 trial

10.1093/clinchem/hvaa223 · 2020 · External reference

The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer

10.1158/1078-0432.ccr-20-4699 · 2021 · External reference

Circulating tumor DNA as a marker of minimal residual disease after radical resection of colorectal liver metastases

2022 · External reference

Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: preliminary results from a prospective study

10.1016/j.ejso.2025.109706 · 2025 · External reference

Circulating tumor DNA predicts early recurrence following locoregional therapy for oligometastatic colorectal cancer

2024 · External reference

Minimal residual disease using a plasma-only circulating tumor DNA assay to predict recurrence of metastatic colorectal cancer following curative intent treatment

10.1158/1078-0432.ccr-23-3660 · 2024 · External reference

ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine

2021 · External reference

The prognostic utility of KRAS mutations in tissue and circulating tumour DNA in colorectal cancer patients

10.3390/gastroent15010008 · 2024 · External reference

Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases

10.1002/ijc.33924 · 2022 · External reference

Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer

10.1038/s41416-023-02300-3 · 2023 · External reference

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy

10.1016/j.ejca.2015.06.118 · 2015 · External reference

RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with Anti-EGFR antibodies in patients with metastatic colorectal cancer

10.1200/po.20.00109 · 2020 · External reference

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

10.1136/esmoopen-2020-000847 · 2020 · External reference

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: individual patient pooled analysis of three cohort studies

10.1002/ijc.33312 · 2021 · External reference

Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III Colon cancer

10.1001/jamaoncol.2019.3616 · 2019 · External reference

Circulating tumour cells & circulating tumour DNA in patients with resectable colorectal liver metastases (MIRACLE): a prospective, observational biomarker study

10.1016/j.eclinm.2025.103406 · 2025 · External reference

Evaluation of molecular residual disease by a fixed panel in resectable colorectal cancer

10.4143/crt.2023.1371 · 2024 · External reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

10.1016/j.ejca.2008.10.026 · 2009 · External reference

Post-treatment surveillance in colorectal cancer

10.2478/v10019-010-0018-8 · 2010 · External reference

Prognostic value of the postoperative carcinoembryonic antigen level in colorectal cancer: a meta-analysis

10.1002/wjs.12349 · 2024 · External reference

Carcinoembryonic Antigen

2025 · External reference

Evaluation of recurrence risk after curative resection for patients with stage I to III colorectal cancer using the hazard function: retrospective analysis of a single-institution large cohort

10.1097/sla.0000000000004058 · 2022 · External reference

Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study

10.1001/jamaoncol.2023.5098 · 2024 · External reference

Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis

10.1007/s00384-022-04144-4 · 2022 · External reference

The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA

10.1002/1878-0261.12729 · 2020 · External reference

Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients

10.1016/j.jmoldx.2018.07.005 · 2018 · External reference

Performance of streck cfDNA blood collection tubes for liquid biopsy testing

10.1371/journal.pone.0166354 · 2016 · External reference

Clinical practice guideline for blood-based circulating tumor DNA assays

10.3343/alm.2023.0389 · 2024 · External reference

Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma

10.1007/s00216-015-8846-4 · 2015 · External reference

Extraction of cell-free DNA: evaluation of efficiency, quantity, and quality

10.1016/j.jmoldx.2024.01.008 · 2024 · External reference

Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: a systematic review and diagnostic accuracy meta-analysis

10.1016/j.ctrv.2025.103066 · 2026 · External reference